160 related articles for article (PubMed ID: 35813302)
1. Analysis of EZH2 Genetic Variants on Triple-Negative Breast Cancer Susceptibility and Pathology.
Liu LC; Chien YC; Wu GW; Hua CH; Tsai IC; Hung CC; Wu TK; Pan YR; Yang SF; Yu YL
Int J Med Sci; 2022; 19(6):1023-1028. PubMed ID: 35813302
[TBL] [Abstract][Full Text] [Related]
2. Effects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology.
Su KJ; Lin CW; Chen MK; Yang SF; Yu YL
Am J Cancer Res; 2015; 5(11):3475-84. PubMed ID: 26807327
[TBL] [Abstract][Full Text] [Related]
3. Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.
Yu YL; Su KJ; Hsieh YH; Lee HL; Chen TY; Hsiao PC; Yang SF
PLoS One; 2013; 8(9):e74870. PubMed ID: 24040354
[TBL] [Abstract][Full Text] [Related]
4. The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females.
Tao R; Chen Z; Wu P; Liu C; Peng Y; Zhao W; Hu C; Feng J
Tumour Biol; 2015 Dec; 36(12):9849-55. PubMed ID: 26162541
[TBL] [Abstract][Full Text] [Related]
5. Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features.
Yu YL; Su KJ; Hsieh MJ; Wang SS; Wang PH; Weng WC; Yang SF
PLoS One; 2014; 9(4):e93635. PubMed ID: 24691023
[TBL] [Abstract][Full Text] [Related]
6. Functional relationship of SNP (Ala490Thr) of an epigenetic gene
Gautam N; Verma H; Choudhary S; Kaur S; Silakari O
J Genet; 2021; 100():. PubMed ID: 34825659
[No Abstract] [Full Text] [Related]
7. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
8. Association of
Shih LC; Tsai CW; Lin TC; Wang YC; He JL; Hsu CL; Hsia TC; Tsai FJ; Yang JS; Hsu YM; Bau DT; Chang WS
In Vivo; 2022; 36(6):2669-2677. PubMed ID: 36309370
[TBL] [Abstract][Full Text] [Related]
9. Association of Enhancer of Zeste 2 (EZH2) Genotypes with Bladder Cancer Risk in Taiwan.
Chang WS; Liao CH; Tsai CW; Hu PS; Wu HC; Hsu SW; Hsiao CL; Hsu CH; Hung YW; Bau DT
Anticancer Res; 2016 Sep; 36(9):4509-14. PubMed ID: 27630289
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
11. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model.
Monterroza L; Parrilla MM; Samaranayake SG; Rivera-Rodriguez DE; Yoon SB; Bommireddy R; Hosten J; Barragan LC; Marcus A; Dobosh BS; Selvaraj P; Tirouvanziam R
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791429
[TBL] [Abstract][Full Text] [Related]
13. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk.
Belpinati F; Malerba G; Dal Toè M; Ceccuzzi L; Rodolfo M; Poli A; Turco A; Vergani E; Sangalli A; Gomez-Lira M
Exp Dermatol; 2020 Oct; 29(10):980-986. PubMed ID: 32748461
[TBL] [Abstract][Full Text] [Related]
15. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.
Yoon KA; Gil HJ; Han J; Park J; Lee JS
J Thorac Oncol; 2010 Jan; 5(1):10-6. PubMed ID: 19901851
[TBL] [Abstract][Full Text] [Related]
17. Association between EZH2 Genetic Variants and Hepatocellular Carcinoma in a Chinese Han Population.
Li S; Sun S; Yu S; Dong Z; Jiang K; Xiang L; Li H
Clin Lab; 2018 Jan; 64(1):85-91. PubMed ID: 29479874
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients.
Peng W; Tang W; Li JD; He RQ; Luo JY; Chen ZX; Zeng JH; Hu XH; Zhong JC; Li Y; Ma FC; Xie TY; Huang SN; Ge LY
PeerJ; 2022; 10():e13708. PubMed ID: 35846880
[TBL] [Abstract][Full Text] [Related]
19. Correlations of
Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
[TBL] [Abstract][Full Text] [Related]
20. EZH2 Expression and Survival for ER+/tamoxifen Treated Breast Cancer Patients with rs2302427 C>G: A Novel Prognostic and Risk Predictive Biomarker.
Gautam N; Kaur S; Kashyap S
Arch Med Res; 2023 Jul; 54(5):102852. PubMed ID: 37438214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
